{
    "xml": "<topic id=\"PHP1554\" outputclass=\"drug\" rev=\"1.12\" type=\"drug\" namespace=\"/drugs/ticagrelor\" basename=\"ticagrelor\" title=\"TICAGRELOR\">\n<title>TICAGRELOR</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1203\" namespace=\"/interactions/list-of-drug-interactions/ticagrelor\">Ticagrelor</xref>\n</p>\n<data name=\"vtmid\">704464003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_119773927\" title=\"Antiplatelets\">Antiplatelets</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP50894\" outputclass=\"indicationsAndDose\" rev=\"1.14\" parent=\"/drugs/ticagrelor\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 180&#8239;mg for 1 dose, then 90&#8239;mg twice daily usually for up to 12 months.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Alternative to clopidogrel in patients undergoing percutaneous coronary intervention</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>180&#8239;mg.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51014\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/ticagrelor\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active bleeding</ph>; <ph outputclass=\"contraindication\">history of intracranial haemorrhage</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51055\" outputclass=\"cautions\" rev=\"1.9\" parent=\"/drugs/ticagrelor\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Asthma</ph>; <ph outputclass=\"caution\">bradycardia (unless pacemaker fitted)</ph>; <ph outputclass=\"caution\">chronic obstructive pulmonary disease</ph>; <ph outputclass=\"caution\">discontinue 7 days before elective surgery if antiplatelet effect not desirable</ph>; <ph outputclass=\"caution\">history of hyperuricaemia</ph>; <ph outputclass=\"caution\">patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or coagulation disorders)</ph>; <ph outputclass=\"caution\">second- or third-degree AV block (unless pacemaker fitted)</ph>; <ph outputclass=\"caution\">sick sinus syndrome (unless pacemaker fitted)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50883\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/ticagrelor\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Caution with concomitant use of drugs that increase risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50800\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/ticagrelor\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bruising</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">haemorrhage</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">gastritis</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Confusion</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">raised serum creatinine</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50863\" outputclass=\"pregnancy\" parent=\"/drugs/ticagrelor\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51074\" outputclass=\"breastFeeding\" parent=\"/drugs/ticagrelor\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50963\" outputclass=\"hepaticImpairment\" parent=\"/drugs/ticagrelor\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in moderate or severe impairment&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50718\" outputclass=\"monitoringRequirements\" parent=\"/drugs/ticagrelor\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor renal function 1 month after initiation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50657\" outputclass=\"nationalFunding\" rev=\"1.18\" parent=\"/drugs/ticagrelor\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA236</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ticagrelor for the treatment of acute coronary syndromes (October 2011)</p>\r\n<p>Ticagrelor, in combination with low-dose aspirin, is recommended for up to 12 months as a treatment option in adults with acute coronary syndromes, that is, people:</p>\r\n<ul>\r\n<li>with ST-segment elevation myocardial infarction&#8212;defined as ST elevation or new left bundle branch block on electrocardiogram&#8212;that cardiologists intend to treat with primary percutaneous coronary intervention, <b>or</b>\r\n</li>\r\n<li>with non-ST-segment elevation myocardial infarction (NSTEMI), <b>or</b>\r\n</li>\r\n<li>admitted to hospital with unstable angina&#8212;defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the characteristics defined below. Before ticagrelor is continued beyond the initial treatment, the diagnosis of unstable angina should first be confirmed, ideally by a cardiologist. Characteristics to be used in defining treatment with ticagrelor for unstable angina are:<ul>\r\n<li>age 60 years or older;</li>\r\n<li>previous myocardial infarction or previous coronary artery bypass grafting;</li>\r\n<li>coronary artery disease with stenosis of 50% or more in at least two vessels;</li>\r\n<li>previous ischaemic stroke;</li>\r\n<li>previous transient ischaemic attack, carotid stenosis of at least 50%, or cerebral revascularisation;</li>\r\n<li>diabetes mellitus;</li>\r\n<li>peripheral arterial disease, <b>or</b>\r\n</li>\r\n<li>chronic renal dysfunction (creatinine clearance less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>).</li>\r\n</ul>\r\n</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA236\">www.nice.org.uk/TA236</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP1554-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ticagrelor\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77087\" title=\"Tablet\" namespace=\"/drugs/ticagrelor/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78144\" namespace=\"/treatment-summaries/acute-coronary-syndromes\" title=\"Acute coronary syndromes\" count=\"4\" rel=\"backlink\">Acute coronary syndromes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78186\" namespace=\"/treatment-summaries/antiplatelet-drugs\" title=\"Antiplatelet drugs\" count=\"3\" rel=\"backlink\">Antiplatelet drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1203\" namespace=\"/interactions/list-of-drug-interactions/ticagrelor\" title=\"Ticagrelor\" count=\"1\" rel=\"link\">Ticagrelor</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77087\" namespace=\"/drugs/ticagrelor/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP1554",
    "outputclass": "drug",
    "rev": "1.12",
    "type": "drug",
    "namespace": "/drugs/ticagrelor",
    "basename": "ticagrelor",
    "title": "TICAGRELOR",
    "interactants": [
        {
            "id": "bnf_int_1203",
            "label": "Ticagrelor"
        }
    ],
    "vtmid": "704464003",
    "drugClassification": [
        "Antiplatelets"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome",
                        "html": "In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 180 mg for 1 dose, then 90 mg twice daily usually for up to 12 months.",
                        "html": "<p>Initially 180&#8239;mg for 1 dose, then 90&#8239;mg twice daily usually for up to 12 months.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Alternative to clopidogrel in patients undergoing percutaneous coronary intervention",
                        "html": "Alternative to clopidogrel in patients undergoing percutaneous coronary intervention"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "180 mg.",
                        "html": "<p>180&#8239;mg.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active bleeding",
                "html": "Active bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "history of intracranial haemorrhage",
                "html": "history of intracranial haemorrhage"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Asthma",
                "html": "Asthma"
            },
            {
                "type": "cautions",
                "textContent": "bradycardia (unless pacemaker fitted)",
                "html": "bradycardia (unless pacemaker fitted)"
            },
            {
                "type": "cautions",
                "textContent": "chronic obstructive pulmonary disease",
                "html": "chronic obstructive pulmonary disease"
            },
            {
                "type": "cautions",
                "textContent": "discontinue 7 days before elective surgery if antiplatelet effect not desirable",
                "html": "discontinue 7 days before elective surgery if antiplatelet effect not desirable"
            },
            {
                "type": "cautions",
                "textContent": "history of hyperuricaemia",
                "html": "history of hyperuricaemia"
            },
            {
                "type": "cautions",
                "textContent": "patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or coagulation disorders)",
                "html": "patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or coagulation disorders)"
            },
            {
                "type": "cautions",
                "textContent": "second- or third-degree AV block (unless pacemaker fitted)",
                "html": "second- or third-degree AV block (unless pacemaker fitted)"
            },
            {
                "type": "cautions",
                "textContent": "sick sinus syndrome (unless pacemaker fitted)",
                "html": "sick sinus syndrome (unless pacemaker fitted)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Caution with concomitant use of drugs that increase risk of bleeding.",
                "html": "<p>Caution with concomitant use of drugs that increase risk of bleeding.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Bruising",
                        "html": "Bruising",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haemorrhage",
                        "html": "haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastritis",
                        "html": "gastritis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Confusion",
                        "html": "Confusion",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "raised serum creatinine",
                        "html": "raised serum creatinine",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;toxicity in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in moderate or severe impairment&#8212;no information available.",
                "html": "<p>Avoid in moderate or severe impairment&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor renal function 1 month after initiation.",
                "html": "<p>Monitor renal function 1 month after initiation.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA236",
                        "label": "www.nice.org.uk/TA236"
                    }
                ],
                "fundingIdentifier": "NICE TA236",
                "textContent": "Ticagrelor for the treatment of acute coronary syndromes (October 2011) Ticagrelor, in combination with low-dose aspirin, is recommended for up to 12 months as a treatment option in adults with acute coronary syndromes, that is, people: with ST-segment elevation myocardial infarction&#8212;defined as ST elevation or new left bundle branch block on electrocardiogram&#8212;that cardiologists intend to treat with primary percutaneous coronary intervention, or with non-ST-segment elevation myocardial infarction (NSTEMI), or admitted to hospital with unstable angina&#8212;defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the characteristics defined below. Before ticagrelor is continued beyond the initial treatment, the diagnosis of unstable angina should first be confirmed, ideally by a cardiologist. Characteristics to be used in defining treatment with ticagrelor for unstable angina are: age 60 years or older; previous myocardial infarction or previous coronary artery bypass grafting; coronary artery disease with stenosis of 50% or more in at least two vessels; previous ischaemic stroke; previous transient ischaemic attack, carotid stenosis of at least 50%, or cerebral revascularisation; diabetes mellitus; peripheral arterial disease, or chronic renal dysfunction (creatinine clearance less than 60 mL/minute/1.73 m2).\n\nwww.nice.org.uk/TA236",
                "html": "<p outputclass=\"title\">Ticagrelor for the treatment of acute coronary syndromes (October 2011)</p> <p>Ticagrelor, in combination with low-dose aspirin, is recommended for up to 12 months as a treatment option in adults with acute coronary syndromes, that is, people:</p> <ul> <li>with ST-segment elevation myocardial infarction&#8212;defined as ST elevation or new left bundle branch block on electrocardiogram&#8212;that cardiologists intend to treat with primary percutaneous coronary intervention, <b>or</b> </li> <li>with non-ST-segment elevation myocardial infarction (NSTEMI), <b>or</b> </li> <li>admitted to hospital with unstable angina&#8212;defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the characteristics defined below. Before ticagrelor is continued beyond the initial treatment, the diagnosis of unstable angina should first be confirmed, ideally by a cardiologist. Characteristics to be used in defining treatment with ticagrelor for unstable angina are:<ul> <li>age 60 years or older;</li> <li>previous myocardial infarction or previous coronary artery bypass grafting;</li> <li>coronary artery disease with stenosis of 50% or more in at least two vessels;</li> <li>previous ischaemic stroke;</li> <li>previous transient ischaemic attack, carotid stenosis of at least 50%, or cerebral revascularisation;</li> <li>diabetes mellitus;</li> <li>peripheral arterial disease, <b>or</b> </li> <li>chronic renal dysfunction (creatinine clearance less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>).</li> </ul> </li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA236\">www.nice.org.uk/TA236</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77087",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78144",
                "label": "Acute coronary syndromes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78186",
                "label": "Antiplatelet drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1203",
                "label": "Ticagrelor",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77087",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}